- Home
- XXII vs LYRA Comparison
XXII vs LYRA Comparison
Compare XXII & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- LYRA
- Stock Information
- Founded
- XXII 1998
- LYRA 2005
- Country
- XXII United States
- LYRA United States
- Employees
- XXII N/A
- LYRA N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- LYRA Medical/Dental Instruments
- Sector
- XXII Health Care
- LYRA Health Care
- Exchange
- XXII Nasdaq
- LYRA Nasdaq
- Market Cap
- XXII 7.0M
- LYRA 5.8M
- IPO Year
- XXII N/A
- LYRA 2020
- Fundamental
- Price
- XXII $0.74
- LYRA $24.28
- Analyst Decision
- XXII
- LYRA Buy
- Analyst Count
- XXII 0
- LYRA 2
- Target Price
- XXII N/A
- LYRA $100.00
- AVG Volume (30 Days)
- XXII 289.5K
- LYRA 1.9M
- Earning Date
- XXII 05-13-2025
- LYRA 05-06-2025
- Dividend Yield
- XXII N/A
- LYRA N/A
- EPS Growth
- XXII N/A
- LYRA N/A
- EPS
- XXII N/A
- LYRA N/A
- Revenue
- XXII $23,869,000.00
- LYRA $1,185,000.00
- Revenue This Year
- XXII $22.41
- LYRA N/A
- Revenue Next Year
- XXII $76.35
- LYRA $1,286.17
- P/E Ratio
- XXII N/A
- LYRA N/A
- Revenue Growth
- XXII N/A
- LYRA N/A
- 52 Week Low
- XXII $0.70
- LYRA $3.81
- 52 Week High
- XXII $140.40
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- XXII 32.55
- LYRA 76.38
- Support Level
- XXII $0.72
- LYRA $22.22
- Resistance Level
- XXII $0.77
- LYRA $27.42
- Average True Range (ATR)
- XXII 0.06
- LYRA 4.12
- MACD
- XXII -0.01
- LYRA 2.36
- Stochastic Oscillator
- XXII 5.25
- LYRA 60.76
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.